Posted by Michael Wonder on 04 Mar 2025
Qalsody (tofersen injection) receives conditional marketing authorisation from Health Canada as the first ALS treatment targeting a genetic cause
3 March 2025 - Biogen's second rare disease therapy to be approved in Canada reflects a continued commitment to advancing innovative therapies for diseases with high unmet medical need.
Biogen Canada announced today that Health Canada has issued marketing authorisation with conditions (Notice of Compliance with conditions) for Qalsody (tofersen injection) for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene.
